Market Chameleon (Wed, 3-Dec 4:03 AM ET)
Globe Newswire (Tue, 2-Dec 4:00 PM ET)
Globe Newswire (Tue, 11-Nov 11:50 PM ET)
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Globe Newswire (Tue, 4-Nov 4:30 PM ET)
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Globe Newswire (Mon, 3-Nov 4:30 PM ET)
Globe Newswire (Mon, 3-Nov 4:25 PM ET)
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Globe Newswire (Thu, 30-Oct 4:30 PM ET)
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Globe Newswire (Thu, 30-Oct 3:00 AM ET)
Globe Newswire (Wed, 29-Oct 6:47 PM ET)
DBV Technologies Reports Third Quarter 2025 Financial Results
Globe Newswire (Tue, 28-Oct 4:25 PM ET)
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
DBV Technologies S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol DBVT.
As of December 12, 2025, DBVT stock price declined to $18.37 with 297,114 million shares trading.
DBVT has a beta of 0.17, meaning it tends to be less sensitive to market movements. DBVT has a correlation of 0.00 to the broad based SPY ETF.
DBVT has a market cap of $737.25 million. This is considered a Small Cap stock.
Last quarter DBV Technologies S.A. - American Depositary Shares reported $3 million in Revenue and -$.24 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.52.
In the last 3 years, DBVT traded as high as $23.70 and as low as $2.20.
DBVT has outperformed the market in the last year with a price return of +378.4% while the SPY ETF gained +14.0%. DBVT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +86.1% and +40.3%, respectively, while the SPY returned +4.0% and -0.2%, respectively.
DBVT support price is $18.20 and resistance is $20.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DBVT shares will trade within this expected range on the day.